modelParathyroidHormone
Extends from Pharmacolibrary.Drugs.ATC.H.H05AA03.
Information
| name: | ParathyroidHormone | |
| ATC code: | H05AA03 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 5.35 | L |
| clearance: | 229 | ml/min |
| other parameters in model implementation | ||
Parathyroid hormone (PTH) is an endogenous peptide hormone used as a diagnostic agent and as recombinant formulations (e.g., teriparatide) for osteoporosis treatment. Full-length recombinant PTH (rhPTH 1-84, ATC code H05AA03) is approved for hypoparathyroidism. Its actions include increasing blood calcium levels by stimulating osteoclasts, renal calcium reabsorption, and activating vitamin D.
Pharmacokinetics
Pharmacokinetic parameters following a single subcutaneous administration of recombinant human parathyroid hormone (rhPTH 1-84) 100 μg in healthy adult subjects, mixed sex.
References
Stratford, R, et al., & Ponnapakkam, T (2014). Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct. Journal of pharmaceutical sciences 103(2) 768–775. DOI:10.1002/jps.23843 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24399637
Liu, Y, et al., & Shi, S (2014). Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects. Clinical therapeutics 36(6) 940–952. DOI:10.1016/j.clinthera.2014.03.015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24793535
Liu, Y, et al., & Zeng, F (2012). Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers. Basic & clinical pharmacology & toxicology 110(2) 154–161. DOI:10.1111/j.1742-7843.2011.00768.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21771277
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)